Eli Lilly to Build Biotech 'App Store' with $7.3B
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly plans to use its $7.3 billion cash reserve to fund an "App Store" for biotech scientists
- Eli Lilly is backing the platform push with a 2025 data center running 1,016 Blackwell chips and active AI collaborations with small biotechs for drug discovery
Why it matters: Eli Lilly is steering $7.3 billion in cash toward AI infrastructure and an external-facing platform — a 1,016-Blackwell-chip data center plus a planned "App Store" — rather than spending it on traditional in-house drug development. For small biotechs, the arrangement opens access to Lilly-funded AI tools they could not afford to build alone, giving Lilly a first-mover claim on the data-and-tools layer of pharmaceutical R&D.
